Damora Therapeutics (DMRA) vs Janux Therapeutics (JANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed Janux Therapeutics (JANX) over the past year, gaining 12.9% versus a loss of 21.0%. Over five years, JANX leads with a -15.2% price change compared with -76.3% for DMRA. Damora Therapeutics is the larger company by market cap ($1.27 billion vs $1.12 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | JANX |
|---|---|---|
| Share price | $20.55 | $18.37 |
| Market cap | $1.27B | $1.12B |
| 1-day change | +1.53% | +2.51% |
| YTD return | -12.04% | +29.86% |
| 1-year return | +12.95% | -21.02% |
| 5-year return | -76.33% | -15.19% |
| EPS (TTM) | $-0.25 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $35.34 |
| 52-week low | $4.95 | $12.12 |
| Distance from 52-week high | -46.38% | -48.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +128.18% | +97.28% |
| Average volume | 539.81K | 836.60K |
| Shares outstanding | 61.74M | 61.14M |
| Employees | 7 | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed JANX by 34.0 percentage points over the past year.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 113 employees
DMRA vs JANX FAQ
Which is bigger, Damora Therapeutics or Janux Therapeutics?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.27B compared with $1.12B for Janux Therapeutics (JANX).
Which stock has performed better over the past year, DMRA or JANX?
DMRA returned +12.95% over the past 12 months, compared with -21.02% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and Janux Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.